Drug Approval | September 16, 2025
Rona submits IND for GalNAc-conjugated siRNA targeting obesity
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Cagrilintide represents a novel approach to obesity management
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Triggering global regulatory submissions this year for the treatment of obesity
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Subscribe To Our Newsletter & Stay Updated
